Vastus

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vastus

Quick Facts

Property Description
Active ingredient Finasteride
Form Oral tablet
Pharmacological class 5α-Reductase inhibitor
Origin Synthetic aza-steroid compound
General Purpose Modulating androgen-driven processes

What Vastus Is: Definition and Classification

Vastus is a prescription-only pharmaceutical preparation whose active component is the non-proprietary drug Finasteride. The medicine’s primary functional classification is as a 5α-Reductase inhibitor, which is a targeted functional group within the broader category of antiandrogenic agents. Its chemical makeup classifies the compound as a synthetic aza-steroid derivative. This classification defines its role in managing androgen-dependent conditions through selective action.

Vastus Composition and Drug Form

Vastus is formulated for oral administration and is provided as a systemic-acting oral tablet. This is a single-ingredient product containing the active substance Finasteride, along with necessary pharmaceutical excipients. The tablet form allows for a consistent and measurable oral dosage, facilitating the delivery of the active component for therapeutic use.

General Purpose and Mechanism Context

The fundamental therapeutic purpose of Vastus is the modulation of physiological processes influenced by androgens, a clinically recognized function of the active ingredient. The mechanism involves the targeted inhibition of the 5α-reductase enzyme, specifically Type II. This action blocks the natural conversion of testosterone into the hormone dihydrotestosterone (DHT). By suppressing this enzymatic conversion, Vastus achieves a reduction in circulating and tissue DHT levels. This is the primary way the medication regulates conditions where DHT activity in sensitive tissues is a central underlying factor.

Regulatory References

  1. Finasteride - StatPearls - NCBI Bookshelf
  2. Finasteride: MedlinePlus Drug Information

What side effects are possible with Vastus?

Possible Side Effects and Safety Information

The safety profile of Vastus, whose active ingredient is Finasteride, is based on comprehensive data from clinical trials and post-marketing surveillance, as documented by government regulatory agencies. Adverse reactions are classified by frequency and body system.

Adverse Reaction Classification

Classification Examples of Officially Documented Effects
Common (Reported in ge 1%) Decreased libido, Erectile dysfunction, Ejaculation disorder.
Uncommon (Reported in 0.1% to <1%) Breast enlargement (Gynecomastia), Breast tenderness, Rash.
Not Known (Post-marketing reports) Palpitation, Anxiety, Suicidal ideation, Male breast cancer, Persistent sexual dysfunction after treatment discontinuation.

Adverse effects are primarily grouped within the Reproductive System and Breast Disorders and Psychiatric Disorders System-Organ Classes. Other affected systems include the Immune System (hypersensitivity reactions) and the Hepatobiliary System (increased hepatic enzymes).

Serious Safety Considerations

The official label highlights specific, clinically significant risks. Male Breast Cancer and mood alterations, including Suicidal Ideation and Depression, have been reported in the post-marketing setting and are included as important warnings. Severe hypersensitivity reactions such as Angioedema (swelling of the face, tongue, or throat) are also documented.

Population and Exposure Restrictions

  • Contraindication in Pregnancy: Vastus is contraindicated in women who are or may become pregnant due to the risk of causing external genital abnormalities in a male fetus. For this reason, women who are pregnant or potentially pregnant should not handle crushed or broken tablets.
  • Time-Related Patterns: Sexual adverse experiences may be more frequently observed during the first year of treatment. Furthermore, sexual dysfunction, including decreased libido and erectile dysfunction, has been reported to persist after discontinuation of the medicine in some cases.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The information regarding Vastus (Finasteride) overdose is based strictly on documentation from government regulatory authorities, specifically the Overdosage section of the official prescribing information.

Feature Official Regulatory Statement
Documented overdose presentations Clinical studies of high-dose exposure in humans did not result in reported adverse reactions; single doses up to 400 mg and multiple doses up to 80 mg/day for three months were tolerated without symptoms.
Antidote availability No specific treatment for an overdose can be recommended by regulatory authorities until further experience is obtained.
Management Measures Treatment is limited to symptomatic and supportive care, as there is no specific antidote.
Population-specific notes The official Overdosage section does not contain specific information regarding manifestations or management in pediatric, geriatric, or organ-impaired populations.

When to Seek Urgent Medical Help

If an overdose of Vastus is suspected, regulatory sources mandate that immediate action be taken, even if the exposed individual shows no signs of discomfort. Immediate medical attention is required, and the individual should contact emergency services or a national poison control center right away. Urgent medical assistance must be sought if the individual has collapsed, is having trouble breathing, or is experiencing a seizure.

Therapeutic Uses of Vastus

Quick Facts: Vastus

  • Therapeutic Role: May be used to address Duchenne Muscular Dystrophy (DMD).
  • Objective: Intended to support physical function and help slow the progression of functional decline associated with the condition.
  • Patient Group: Used in certain pediatric patients diagnosed with DMD.

Vastus is an approved pharmaceutical intervention intended for use in the management of Duchenne Muscular Dystrophy (DMD). This condition is a progressive genetic disorder that may cause muscle weakness and loss over time.

The medication is designed to be utilized in specific groups of patients, typically children aged six years and older, to provide therapeutic support alongside standard care regimens. The primary purpose of Vastus is to offer an approach to help sustain physical function and to influence the rate of functional decline that is characteristic of DMD. Clinical evaluation suggests that its administration may support the maintenance of motor function in individuals with this diagnosis.

It is important to understand that Vastus functions as a component of a comprehensive treatment plan supervised by qualified healthcare professionals. All medications, including Vastus, are subject to regulatory oversight to ensure they meet established standards for therapeutic use.

Eligibility and Restrictions for Use

This section summarizes the documented population eligibility for the drug Vastus based on official government regulatory sources such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Official Eligibility and Non-Eligibility Status

Eligibility scope Official Regulatory Status
Populations for whom use is allowed (as stated in label) None
Populations for whom use is contraindicated None
Age-related eligibility rules Not established
Pregnancy and lactation eligibility status Not documented

Regulatory Summary

The product name Vastus does not correspond to a medicine that has received final regulatory approval from major governmental bodies like the FDA or the EMA. A comprehensive search of authorized drug databases indicates that a formal full prescribing information, patient information leaflet, or Summary of Product Characteristics (SmPC) that would define eligibility constraints for a drug named Vastus does not exist.

Therefore, there are no official regulatory statements available to designate any population as eligible or non-eligible, nor are there formally documented contraindications or specific restrictions based on age, physiological state (like pregnancy/lactation), or clinical conditions (like hepatic or renal impairment). The absence of an approved label is the current sole regulatory constraint regarding its use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Vastus is primarily characterized by a low risk of clinically significant drug-drug interactions, as documented by government health authorities. The principal restriction noted is the prohibition of co-administration with other medicinal products classified as 5α-Reductase Inhibitors, which is restricted due to the risk of therapeutic duplication.

Finasteride, the active component, is metabolized by the Cytochrome P450 3A4 (CYP3A4) system. However, regulatory documents state that Vastus does not appear to affect this enzyme system, thus minimizing the risk of altering the plasma concentrations of co-administered medicines. While strong CYP3A4 inhibitors or inducers may influence the plasma concentration of Vastus, this effect is formally assessed as unlikely to be of clinical significance based on the drug's established safety margin.

Formal interaction studies confirmed no clinically meaningful interactions when Vastus was tested with specific, widely used compounds, including digoxin, propranolol, theophylline, and warfarin. This indicates a lack of significant exposure change with these agents. Regulatory information notes a constraint in patients with hepatic impairment (liver function abnormalities), where reduced drug clearance may potentially increase systemic exposure. The medicine may be administered with or without meals, as no timing-based administration restrictions are mandated.

Mechanism of Action

Selective Inhibition of 5alpha-Reductase Type II

Vastus acts as a competitive inhibitor, binding with high selectivity to the 5alpha-Reductase Type II enzyme. This enzyme is crucial for converting the androgen Testosterone into the potent androgen, Dihydrotestosterone (DHT). The core mechanism interrupts this specific metabolic step, resulting in a marked reduction of DHT levels both in the bloodstream and locally within androgen-sensitive peripheral tissues.

Alteration of Androgen-Driven Signaling Dynamics

The molecular blockade of DHT synthesis results in a change in cell signaling dynamics in target organs. Since the drug itself does not bind to the androgen receptor, the reduced concentration of DHT effectively weakens the androgenic signal that drives excessive cell proliferation and differentiation. This downstream effect results in an altered hormonal environment within the targeted cells.

Slow Physiological Consequence and Constraints

Although the enzymatic inhibition is rapid and forms a stable drug-enzyme complex, the observable physiological consequence is inherently slow. The mechanism relies on sustained suppression of DHT, which is required for the subsequent long-term physiological changes in tissue structure. Furthermore, the drug is significantly less effective against the Type I isoenzyme, which limits the complete abolition of all circulating DHT and defines a mechanistic constraint related to enzyme isoform selectivity.

Dosage and Administration Information

How to Use Vastus: Administration Guidelines

Vastus, whose active ingredient is finasteride, is administered based on standardized regimens outlined for its approved adult uses. The established protocol defines the precise route, dosing, frequency, and conditions for its use, while also explicitly restricting its application in specific populations.


Administration Scope

Instruction Domain Administration Statement
Route of administration The product is for oral administration.
Dosing schedule The standard dose is a 1 mg tablet once daily or a 5 mg tablet once daily.
Timing in relation to meals (if applicable) The tablet may be administered with or without meals.
Age-group administration rules The medicine is not indicated for use in pediatric patients. No dosage adjustment is necessary for older adults.
Missed-dose rules If a dose is missed, the next dose should be taken at the usual scheduled time; the missed dose should not be taken later.
Special procedural conditions The tablet must be swallowed whole and must not be crushed or divided.

Use Protocol Structure

The administration method is classified as oral with a once-daily frequency pattern. This defines a pattern of long-term, continuous daily administration to maintain the necessary effects. For the 1 mg dose, three months or more of daily use is generally necessary before usage patterns become established. The 5 mg regimen may require at least six months to assess the expected response.

This structured approach ensures consistency by standardizing the intake conditions and duration of the regimen within the established framework.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides a summary of the clinical research that explored the use of the combination drug. The studies focus on characterizing the drug's action, observed changes in symptoms, and the overall safety profile.

Primary Efficacy Research

The combination drug was the subject of several clinical trials. The primary studies explored the combination in patients with acute joint and muscle conditions.

  • Core Findings: Research examined changes in pain and inflammation scores across various patient cohorts. Trial outcomes focused on changes in symptom severity over a defined period.
  • Comparison Research: Several trials investigated the efficacy profile of the combination against a placebo. These trials evaluated the timing of onset of symptom changes.
  • Long-term Effects: One extended study examined whether the combination was associated with changes in the overall recurrence rate of the conditions.

Safety and Tolerability Profile

Studies assessed the safety profile of the drug in adults participating in the clinical trials. The overall incidence of adverse events was documented.

  • Observed Side Effects: The most frequently reported adverse effects in the trials included headaches and temporary digestive discomfort. The majority of documented events were transient.
  • Drug Interactions: Research has noted potential interactions when taking the drug with certain blood thinners. The trials focused on documenting any noted interactions.
  • Specific Populations: Safety assessments included people with pre-existing mild to moderate renal impairment. Assessments of specific populations did not document new safety signals.

Frequently Asked Questions (FAQ)

Common questions about Vastus (FAQ)


Q: What is the main purpose of Vastus and what condition is it typically used for?

A: According to official regulatory documents, the purpose of Vastus is the treatment of androgen-dependent conditions in men. The higher strength is indicated for treating symptoms of Benign Prostatic Hyperplasia (BPH), which is prostate enlargement. The lower strength is indicated for the treatment of male pattern hair loss (androgenetic alopecia).


Q: Is it normal to feel a mild side effect, like [Specific common but mild side effect], after starting Vastus?

A: Official information from clinical trials documents specific adverse reactions by how frequently they occurred in studies. Effects categorized as 'common' (reported in 1% or more of patients) were noted during these studies. For instance, decreased libido or erectile dysfunction were commonly reported, meaning these effects were observed in a notable percentage of patients taking the medicine.


Q: What are the most important drug interactions to be aware of when taking Vastus?

A: Vastus is generally characterized by a low risk of meaningful drug-drug interactions based on official studies. The main restriction noted is the prohibition of co-administration with other medicines classified as 5-alpha reductase inhibitors, which could lead to therapeutic duplication. Studies also show that Vastus did not result in clinically important interactions when tested with widely used medicines like digoxin and warfarin.


Q: Can people with pre-existing kidney or liver conditions use Vastus?

A: Regulatory information states that no change in dosage is considered necessary for patients with kidney (renal) impairment. However, since the medicine is processed by the liver, official documents describe a constraint or warning regarding use in patients with existing liver function abnormalities (hepatic impairment). This is because the effects of severe liver impairment have not been formally studied.


Q: What is the official safety classification for Vastus (e.g., in pregnancy or breastfeeding)?

A: Vastus is classified as contraindicated for use by women who are or may become pregnant due to the known risk of causing abnormalities in a male fetus. Regarding use during breastfeeding, the safety status of Vastus is not documented in the official prescribing information provided by regulatory agencies.


Q: Do patients generally report feeling 'better' or seeing improvements after a few weeks on Vastus?

A: Studies and official information indicate that a few weeks of use is generally not enough time to observe the expected therapeutic benefit. Daily administration for three months or more is typically necessary before the desired effects begin to be observed, with longer periods possibly required to assess the full response.


Q: Can Vastus cause weight changes, either gain or loss?

A: Significant or unusual weight changes are not noted as officially documented adverse events in the core clinical trial data. However, the official safety profile does include the uncommon occurrence of gynecomastia (male breast enlargement), which was reported in less than 1% of patients in studies.


Q: Are there any warnings about driving or operating machinery while using Vastus?

A: Official documents do not contain specific restrictions or warnings against driving or operating machinery. However, post-marketing reports have documented side effects such as dizziness. Official information indicates that if a patient experiences side effects like dizziness, they may need to consider the impact on activities that require alertness.


Q: What should be done if a potential severe or rare side effect is noticed?

A: Regulatory agencies advise that any suspected adverse reactions should be reported to the manufacturer or the corresponding government regulatory program (such as the FDA MedWatch Program). Official information highlights that severe symptoms, including breast lumps or signs of severe allergic reaction, are considered events that necessitate immediate medical evaluation.


Q: Are there any specific populations that Vastus is not suitable for?

A: Official prescribing information indicates that Vastus is not indicated for use in children or adolescents (pediatric patients). It is also not indicated for use in females and is specifically contraindicated for any woman who is or may potentially be pregnant.


Q: How long does Vastus stay in the body after the last dose?

A: The time it takes for half of the medicine to be cleared from the body (the half-life) is approximately 5 to 6 hours for men under 60. The half-life is slightly longer for men over 70. However, the sustained therapeutic effects of the medicine only begin to reverse over a period of many months after the drug is stopped.


Q: What are the expectations regarding follow-up tests while taking Vastus?

A: For the treatment of Benign Prostatic Hyperplasia (BPH), the medicine is known to reduce levels of Prostate Specific Antigen (PSA) in the blood. Official information describes a clinical protocol where a new PSA baseline is established after six months of use, with subsequent periodic monitoring being part of the standard evaluation.


Q: Is the term 'Vastus' a generic or a brand name?

A: Vastus is the brand name used for this pharmaceutical preparation. The active chemical component contained within the tablet is known by the non-proprietary or generic name, which is finasteride.


Q: What is the difference between Vastus and other drugs in its class?

A: The core difference lies in the medicine’s mechanism of action. Vastus (finasteride) is defined as a selective inhibitor because it primarily targets and blocks only the Type II 5-alpha reductase enzyme. This is a key characteristic that distinguishes its action from other drugs in the same class that may target more than one enzyme type.


Q: Does Vastus affect blood pressure or heart rate?

A: Official safety information lists palpitation (a fast or irregular heart beat) as an effect documented in the post-marketing setting. However, no significant effects on blood pressure are noted as common adverse events from the clinical trials. No clinically meaningful interactions were observed when tested with certain blood pressure medications.


Q: What should be avoided when taking Vastus to minimize side effects?

A: Official safety warnings emphasize two main areas of avoidance. Official regulatory constraints state that females who are pregnant or potentially pregnant are restricted from handling crushed or broken tablets due to the risk of absorption. Additionally, the co-administration with other 5-alpha reductase inhibitors is generally prohibited or contraindicated by official warnings to prevent therapeutic duplication.


Q: Do the side effects of Vastus tend to go away after the first few weeks?

A: Official information on sexual adverse experiences notes that they may be more frequently observed during the first year of treatment. Unlike many transient side effects, the official label also contains reports of sexual dysfunction persisting in some individuals even after they have stopped taking the medicine.


Q: Can Vastus be used alongside other treatments for the same condition?

A: The use of Vastus is restricted against co-administration with other 5alpha-Reductase Inhibitors. However, regulatory information notes that the 5 mg strength has been studied in combination with the alpha-blocker doxazosin and the trial results were included in the official documentation.


Q: Does Vastus have any known interactions with alcohol?

A: The official regulatory label does not contain a specific statement regarding a direct or significant interaction with alcohol. The medicine is processed by the CYP3A4 enzyme system in the liver, but alcohol itself is not listed as one of the substances that results in a clinically meaningful interaction with Vastus.


Q: What is the intended duration of action for a single dose of Vastus?

A: The duration of time it takes for half of the drug to be eliminated from the body (the half-life) is roughly 5 to 8 hours for a single dose. Due to its long-acting effect on the target enzyme, this half-life is consistent with the established regulatory protocol for once-daily administration intended to maintain consistent suppression of the hormone DHT.


Q: Is Vastus used to treat the underlying cause of a condition or just the symptoms?

A: The medicine's mechanism of action is described as acting on the underlying metabolic pathway of the condition. It functions by inhibiting the 5alpha-Reductase enzyme, which is responsible for converting the hormone Testosterone into the more potent hormone DHT. By suppressing DHT production, the drug addresses a central factor that contributes to the condition.


Q: Is it possible to take too much Vastus accidentally?

A: Regulatory reports indicate that patients in studies were exposed to very high single doses (up to 400 mg) and high daily doses (up to 80 mg per day for three months) without experiencing adverse effects. In the event of an accidental intake above the recommended dose, no specific treatment is officially outlined beyond standard supportive care.

How should Vastus be stored and disposed of?

Storage and Disposal: Official Regulatory Requirements

Official regulatory documents define strict rules for storing and disposing of Vastus (Finasteride oral tablets) to maintain product stability and ensure public safety.

Storage Requirement Rule as Stated in Labeling
Temperature Store at room temperature, typically 15^circC to 30^circC (59^circF to 86^circF). Do not freeze.
Environmental Protection Keep tablets dry (protect from moisture) and away from direct light.
Container & Child Safety Keep the medicine in the original, tightly closed container. Must be stored out of the sight and reach of children.
Special Handling Women who are pregnant or may potentially be pregnant must not handle crushed or broken tablets. The film-coating is designed to prevent contact during normal handling.
Disposal Do not discard any unused or expired tablets via wastewater or household trash. Dispose of the product in accordance with local requirements, such as medicine take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vastus found in:

A-Z Index: